Screener
Arcutis Biotherapeutics, Inc. ARQT Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from maturities and sales of marketable securities | 101,346 | 129,121 |
| Milestone payment for intangible asset | — | (10,000) |
| Purchases of property and equipment | (158) | (686) |
| Net cash provided by (used in) investing activities | (26,556) | 29,173 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of common stock upon exercise of stock options | 2,428 | 456 |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 1,629 | 1,319 |
| Payment of debt prepayment penalty | (1,000) | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s investing cash flow?
- Arcutis Biotherapeutics, Inc. (ARQT) reported investing cash flow of -$15.22M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s investing cash flow changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s investing cash flow decreased by 187.4% year-over-year, from $17.42M to -$15.22M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Arcutis Biotherapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude